美股异动 | MRT-8102一期试验数据积极 Monte Rosa Therapeutics(GLUE.US)盘前暴涨超42%

智通财经
Jan 07

智通财经APP获悉,周三,Monte Rosa Therapeutics(GLUE.US)盘前暴涨超42%,报22.76美元。消息面上,Monte Rosa Therapeutics正在进行的MRT-8102一期试验的中期数据显示,在心血管和心脏代谢疾病中C反应蛋白水平降低。

在心血管疾病(CVD)风险升高的受试者中,正处于研发阶段用于治疗NLRP3/IL-1/IL-6驱动的炎症性疾病的NEK7靶向分子胶降解剂MRT-8102显示出快速且持久的全身炎症减轻效果。经过四周的MRT-8102治疗后,C反应蛋白(CRP)水平下降了85%,94%的研究参与者达到了低于2 mg/L的CRP值,这一阈值与降低的心血管疾病(CVD)风险相关联。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10